What is AskBio?
AskBio is at the forefront of molecular medicine, dedicated to pioneering gene therapeutics through groundbreaking research, synthetic biology, and scalable cGMP manufacturing. The company's robust pipeline targets a range of severe diseases, including neuromuscular, central nervous system, metabolic, and cardiovascular conditions. With a substantial portfolio of over 775 molecular and genetic medicine patents and an extensive library of capsids and promoters, AskBio possesses a strong foundation for innovation. Its global operations span research centers in Philadelphia, PA; Columbus, OH; and Paris, with European headquarters in Edinburgh and global headquarters in RTP, NC. Manufacturing capabilities are located in San Sebastian, Spain. As a wholly owned, independently operated subsidiary of Bayer, AskBio leverages significant resources to drive its mission forward.
How much funding has AskBio raised?
AskBio has raised a total of $4.2M across 2 funding rounds:
Grant
$1.6M
Grant
$2.6M
Grant (2004): $1.6M with participation from Muscular Dystrophy Association
Grant (2020): $2.6M led by Scottish Enterprise
Key Investors in AskBio
Muscular Dystrophy Association
The Muscular Dystrophy Association (MDA) is a non-profit organization dedicated to combating muscular dystrophy and related diseases through research funding and medical services.
Scottish Enterprise
Scottish Enterprise is a national economic development agency that supports businesses and entrepreneurs in Scotland, fostering innovation and growth.
What's next for AskBio?
The recent major strategic investment in AskBio signals a strong confidence in its gene therapy pipeline and manufacturing capabilities. This capital infusion is expected to accelerate the development and commercialization of its transformative therapeutic candidates. With Bayer's backing and its own extensive intellectual property, AskBio is well-positioned to expand its clinical trials, enhance its manufacturing scale, and solidify its market leadership in the rapidly evolving field of gene therapy. The company's focus on addressing critical unmet medical needs through advanced molecular medicine is set to drive significant growth and impact in the coming years.
See full AskBio company page
